Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4IG16)

• Drug Name: ZYGK-1 Drug Info
• Synonyms: Glucokinase activator (oral, diabetes), Zydus-Cadila

Indication

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM4IG16

Molecule-Related Drug Atlas

Drug(s) Targeting Glucokinase (GCK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LY-2599506	DMMI0RH	Diabetic complication	5A2Y	Phase 2	[3]
AMG 151	DMGOFL3	Type-2 diabetes	5A11	Phase 2	[3]
PF-04991532	DM94NBE	Diabetic complication	5A2Y	Phase 2	[4]
GK1-399	DMLFSMX	Diabetic complication	5A2Y	Phase 2	[5]
LY-2608204	DM4EF9Y	Type-2 diabetes	5A11	Phase 2	[6]
PF-04937319	DMQMF4O	Type-2 diabetes	5A11	Phase 2	[7]
AZD1656	DMUE90I	Diabetic complication	5A2Y	Phase 2	[8]
TTP399	DMBKQSZ	Type 2 diabetes	5A11	Phase 2	[9]
HMS5552	DMRYM03	Type-2 diabetes	5A11	Phase 1	[10]
BMS-820132	DMCX0H7	Type-2 diabetes	5A11	Phase 1	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucokinase (GCK)	TTDLNGZ	HXK4_HUMAN	Activator	[2]

References

• [1] ClinicalTrials.gov (NCT01472809) A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral ZYGK1 in Healthy Volunteers. U.S. National Institutes of Health.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2798).
• [3] This week in therapeutics Endocrine disease. SciBX 2(37); doi:10.1038/scibx.2009.1408. Sept. 24, 2009
• [4] The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats. PLoS One. 2014 May 23;9(5):e97139.
• [5] Clinical pipeline report, company report or official report of vTv Therapeutics, NCT02405260.
• [6] Clinical pipeline report, company report or official report of Eli Lilly.
• [7] Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. Diabetes Obes Metab. 2015 Aug;17(8):751-9.
• [8] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [9] Clinical pipeline report, company report or official report of vTv Therapeutics.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] Utilization of the Zucker Diabetic Fatty (ZDF) Rat Model for Investigating Hypoglycemia-related Toxicities. Toxicol Pathol. 2015 Aug;43(6):825-37.